Evidence map›Paper›PMID 38724507›Full record

ArticleCell death & disease2024

Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter's syndrome.

Antonella Rigo, Tiziana Vaisitti, Carlo Laudanna, Eleonora Terrabuio, Matilde Micillo, Cristina Frusteri, Beatrice D'Ulivo, Flavia Merigo, Andrea Sbarbati, Kevin Mellert and 10 more

Abstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Antonella RigoCancer Research & Cell Biology Laboratory, Section of Innovation Biomedicine, Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy.
Tiziana VaisittiLaboratory of Functional Genomics, Department of Medical Sciences, University of Turin, Turin, Italy.
Carlo LaudannaSection of General Pathology, Department of Medicine, University of Verona, Verona, Italy.
Eleonora TerrabuioSection of General Pathology, Department of Medicine, University of Verona, Verona, Italy.
Matilde MicilloLaboratory of Functional Genomics, Department of Medical Sciences, University of Turin, Turin, Italy.
Cristina FrusteriCancer Research & Cell Biology Laboratory, Section of Innovation Biomedicine, Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy.
Beatrice D'UlivoSection of General Pathology, Department of Medicine, University of Verona, Verona, Italy.
Flavia MerigoSection of Anatomy and Histology, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Andrea SbarbatiSection of Anatomy and Histology, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Kevin MellertInstitute of Pathology, University Hospital of Ulm, Ulm, Germany.
Peter MöellerInstitute of Pathology, University Hospital of Ulm, Ulm, Germany.
Alessio MontresorSection of General Pathology, Department of Medicine, University of Verona, Verona, Italy.
Arianna Di NapoliDepartment of Clinical and Molecular Medicine, Sapienza University, Sant'Andrea University Hospital, Rome, Italy.ORCID 0000-0002-3159-5380
Roberto CirombellaDepartment of Clinical and Molecular Medicine, Sapienza University, Sant'Andrea University Hospital, Rome, Italy.
Elena ButturiniDepartment of Neuroscience, Biomedicine and Movement Sciences, Biological Chemistry Section, University of Verona, Verona, Italy.
Massimo MassaiaHematology Unit, Hospital S. Croce e Carle, Cuneo, Italy.
Gabriela ConstantinSection of General Pathology, Department of Medicine, University of Verona, Verona, Italy.
Fabrizio VinanteCancer Research & Cell Biology Laboratory, Section of Innovation Biomedicine, Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy.
Silvia DeaglioLaboratory of Functional Genomics, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID 0000-0003-0632-5036
Isacco FerrariniCancer Research & Cell Biology Laboratory, Section of Innovation Biomedicine, Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy. isacco.ferrarini@univr.it.ORCID 0000-0001-9867-8335

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG #23095Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) MFAG #23107
6 · The paper itself

Abstract

Richter's syndrome (RS) is the transformation of chronic lymphocytic leukemia (CLL) into a high-grade B-cell malignancy. Molecular and functional studies have pointed out that CLL cells are close to the apoptotic threshold and dependent on BCL-2 for survival. However, it remains undefined how evasion from apoptosis evolves during disease transformation. Here, we employed functional and static approaches to compare the regulation of mitochondrial apoptosis in CLL and RS. BH3 profiling of 17 CLL and 9 RS samples demonstrated that RS cells had reduced apoptotic priming and lower BCL-2 dependence than CLL cells. While a subset of RS was dependent on alternative anti-apoptotic proteins and was sensitive to specific BH3 mimetics, other RS cases harbored no specific anti-apoptotic addiction. Transcriptomics of paired CLL/RS samples revealed downregulation of pro-apoptotic sensitizers during disease transformation. Albeit expressed, effector and activator members were less likely to colocalize with mitochondria in RS compared to CLL. Electron microscopy highlighted reduced cristae width in RS mitochondria, a condition further promoting apoptosis resistance. Collectively, our data suggest that RS cells evolve multiple mechanisms that lower the apoptotic priming and shift the anti-apoptotic dependencies away from BCL-2, making direct targeting of mitochondrial apoptosis more challenging after disease transformation.

Indexed as

ApoptosisLeukemia, Lymphocytic, Chronic, B-CellMitochondriaProto-Oncogene Proteins c-bcl-2FemaleHumansMaleMiddle AgedBCL2 protein, humanProto-Oncogene Proteins c-bcl-2

Identifiers

PMID38724507
PMCPMC11082225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.